For research use only. Not for therapeutic Use.
KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2[1].
KW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE2 in mouse osteoblastic cells[1].
KW-8232 possesses anti-viral activity against SARS-CoV-2 (EC50 ~1.2 μM )[2].
KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production[1].
| Catalog Number | I045708 |
| CAS Number | 217813-15-5 |
| Synonyms | [3-[bis(4-hydroxyphenyl)methyl]-1-[2-(dimethylamino)ethyl]indol-2-yl]-[4-(2-chlorophenyl)piperazin-1-yl]methanone;methanesulfonic acid |
| Molecular Formula | C37H41ClN4O6S |
| Purity | ≥95% |
| InChI | InChI=1S/C36H37ClN4O3.CH4O3S/c1-38(2)19-24-41-31-9-5-3-7-29(31)34(33(25-11-15-27(42)16-12-25)26-13-17-28(43)18-14-26)35(41)36(44)40-22-20-39(21-23-40)32-10-6-4-8-30(32)37;1-5(2,3)4/h3-18,33,42-43H,19-24H2,1-2H3;1H3,(H,2,3,4) |
| InChIKey | YBHZOINCWYRXCE-UHFFFAOYSA-N |
| SMILES | CN(C)CCN1C2=CC=CC=C2C(=C1C(=O)N3CCN(CC3)C4=CC=CC=C4Cl)C(C5=CC=C(C=C5)O)C6=CC=C(C=C6)O.CS(=O)(=O)O |
| Reference | [1]. Uchii M, et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. Jpn J Pharmacol. 1998 Oct;78(2):241-3. [2]. Shiwei Wang, et al. A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2. bioRxiv. 2020. |
